HCA Healthcare announced a significant cut to its full-year 2026 profit guidance due to an unfavorable change in its payer mix, which reduced revenue by about $400 million in Q2. Following this announcement, HCA's stock price fell nearly 7%. Pomerantz LLP is investigating whether HCA and some of its executives engaged in securities fraud or other unlawful practices. Investors affected are encouraged to contact the law firm as a class action may be pursued.
Kirby McInerney LLP is investigating HCA Healthcare for potential securities fraud following the company's sharp profit guidance cut due to increased uninsured patients affecting revenue by $400 million. The investigation aims to determine if HCA or ...
Wells Fargo has lowered its price target for HCA Healthcare to $369 from $428 following the company's revised 2026 financial outlook. HCA Healthcare reduced its earnings per share forecast to $28.70-$30.50 and narrowed sales guidance to $77-$79.5 bil...
